Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Cancer Immunol Immunother

Search In Journal Title:

Abbravation: Cancer Immunology, Immunotherapy

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/978-1-4615-9465-9_16

Search In DOI:

ISSN

1432-0851

Search In ISSN:
Search In Title Of Papers:

Second International Symposium on Cancer Biology

Authors: Anil Suri Shikha Saini Namita Gupta
Publish Date: 2012/07/18
Volume: 61, Issue: 10, Pages: 1877-1882
PDF Link

Abstract

The second International Symposium on Cancer Biology ISCB was organized from November 14–16 2011 by National Institute of Immunology NII New Delhi India in collaboration with Queen’s University Belfast UK The symposium also coincided with the milestone anniversary celebration of National Institute of Immunology NII New Delhi India The symposium was mainly focused on the sharing of knowledge and dissemination of research data among renowned cancer biologists clinicians and immunologists across the world The symposium addressed the multifaceted issue of cancer with particular emphasis on the discovery of novel tumor antigens tumor immunity immunotherapeutic strategies drugresistance mechanisms and reports of the latest trials being carried out on major cancer types

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy
  2. Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients
  3. Saccharomyces cerevisiae , the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice
  4. Higher numbers of T-bet + intratumoral lymphoid cells correlate with better survival in gastric cancer
  5. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E 2 results in high interleukin-12 production and cell migration
  6. Increase in CD14 + HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
  7. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells
  8. Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma
  9. Epigenetic regulation of immune escape genes in cancer
  10. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis
  11. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses
  12. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle
  13. −509C>T polymorphism in the TGF-β1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection
  14. Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004
  15. Heterogeneity of CD8 + tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies
  16. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma
  17. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
  18. Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells
  19. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms
  20. H 2 O 2 production within tumor microenvironment inversely correlated with infiltration of CD56 dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction
  21. Lenalidomide enhances anti-myeloma cellular immunity
  22. Epidemiology: allergy history, IgE, and cancer
  23. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
  24. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
  25. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
  26. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors
  27. Chordoma and chondrosarcoma gene profile: implications for immunotherapy
  28. Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma
  29. Extracellular adenosine metabolism in immune cells in melanoma
  30. Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity
  31. Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
  32. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies
  33. Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function
  34. Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis
Search Result: